What is the optimal method to transition a patient from intramuscular testosterone injections to a topical testosterone gel or cream?

Transitioning from Intramuscular to Topical Testosterone: A Practical Protocol

Simply switch directly from intramuscular injections to daily topical gel without any washout period or dose overlap, then measure testosterone levels after 1 week of gel use to confirm adequate absorption and adjust the dose accordingly. 1

Step-by-Step Transition Protocol

Timing the Switch

• Discontinue intramuscular testosterone and begin topical gel on the same day—no washout period is required because the goal is to maintain stable testosterone levels throughout the transition. 2, 1
• For patients on weekly IM injections (e.g., 100 mg testosterone cypionate weekly), apply the first dose of gel on the day the next injection would have been due. 1, 3
• For patients on biweekly IM injections (e.g., 200 mg every 2 weeks), initiate gel at the midpoint between injections (day 7) to avoid a trough period, or wait until the next scheduled injection day if testosterone levels remain adequate. 2, 1

Initial Topical Gel Dosing

• Start with 50 mg daily of 1% testosterone gel (e.g., 5 g of gel) or 40.5 mg daily of 1.62% gel (two pump actuations) as the standard initial dose for most men transitioning from IM therapy. 4, 5
• Apply the gel to clean, dry, intact skin of the upper arms and shoulders only—never to the abdomen, genitals, chest, armpits, or knees—and limit the application area to what a short-sleeve t-shirt will cover. 5
• Wash hands immediately with soap and water after application, cover the site with clothing once dry, and avoid swimming or showering for at least 2 hours. 5

Monitoring After the Switch

• Measure serum testosterone after 1 week of continuous daily gel use to confirm steady-state levels have been achieved; this timing is specific to transdermal gels and differs from the 3–6 month interval used for dose-stable patients. 2, 6, 1
• Draw the blood sample at any time of day after at least 1 week of gel use, because gel formulations produce stable 24-hour testosterone levels without the peaks and troughs seen with injections. 2, 6, 1
• Target a mid-normal testosterone range of 400–700 ng/dL; if the level is <350 ng/dL, increase the gel dose by one pump actuation (20.25 mg for 1.62% gel) or 25 mg for 1% gel; if >700 ng/dL, reduce by the same increment. 2, 1, 4, 5

Follow-Up Laboratory Surveillance

• Repeat testosterone measurement at 3–6 months after the transition to confirm stable therapeutic levels, then annually once optimized. 2, 1
• Check hematocrit at 3–6 months and annually thereafter; transdermal gels carry a significantly lower risk of polycythemia (11.3–17.9%) compared with IM injections (43.8%), but monitoring remains mandatory. 1
• Stop testosterone immediately if hematocrit exceeds 54%, evaluate for hypoxia or sleep apnea, and consider restarting at a reduced dose only after normalization. 2, 1
• In men ≥40 years with baseline PSA >0.6 ng/mL, obtain PSA and digital rectal exam at 3–6 months and then annually; refer to urology if PSA rises >1.4 ng/mL within 12 months or if the exam is abnormal. 2, 1

Why This Transition Works

• Testosterone gels produce more stable serum testosterone concentrations than IM injections, eliminating the supraphysiologic peaks (days 2–7) and subtherapeutic troughs (days 13–14) characteristic of biweekly IM dosing. 7
• In a prospective crossover study of HIV-infected hypogonadal men, switching from IM testosterone (100–200 mg weekly) to daily gel (5–10 g/day) reduced peak-trough fluctuations in free testosterone from 26.7 pg/mL to 2.7 pg/mL (p<0.001) and improved quality-of-life scores for physical and emotional well-being. 7
• No washout or overlap period is necessary because the pharmacokinetics of gel allow rapid achievement of steady-state levels within 1 week, and any residual IM testosterone will decline gradually without causing supraphysiologic levels. 1, 7

Common Pitfalls to Avoid

• Do not wait 3–6 months to check the first post-transition testosterone level—this is the monitoring interval for stable therapy, not for dose adjustments; gels require a 1-week check to confirm adequate absorption and guide early titration. 2, 1
• Do not apply gel to the abdomen, genitals, or axillae, as these sites are not FDA-approved and may alter absorption or increase transfer risk to others. 5
• Warn patients about secondary transfer risk: children and women must avoid contact with unwashed or unclothed application sites; patients should wash the site with soap and water before anticipated skin-to-skin contact. 5
• Do not assume equivalent dosing between IM and topical formulations—a patient on 100 mg IM weekly does not automatically require 100 mg of gel daily; start with standard gel dosing (40.5–50 mg daily) and titrate based on measured levels. 1, 4

When to Consider Switching Back to IM

• If maximal gel dosing (e.g., 81 mg daily of 1.62% gel or 100 mg daily of 1% gel) fails to achieve target testosterone levels after 3–6 months, switch back to IM injections because some patients are poor transdermal absorbers. 1
• Patients who develop persistent skin irritation, cannot adhere to daily application, or have concerns about transfer to household contacts may prefer to return to IM therapy. 2, 7